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Abstract A group of eleven sesquiterpene lactones isolated from 
different Asteraceae species from north-western Argentina were 
investigated for their inhibitory action on the estrogen biosynth-
esis. Seven of them, of different skeleton types, were found to 
inhibit the aromatase enzyme activity in human placental 
microsomes, showing IC 5 0 values ranging from 7 to 110 uM. 
The most active were the guaianolides 10-epi-8-deoxycumambrin 
B (compound 1), dehydroleucodin (compound 2) and ludartin 
(compound 3). These compounds were competitive inhibitors with 
an apparent K{ = 4 [iM, K{ = 21 uM and K{ = 23 pJYl, respec-
tively. Compounds 1 and 2 acted as type II ligands to the heme 
iron present in the active site of aromatase cytochrome P450 
(P450arom). Besides, all of them failed to affect the cholesterol 
side-chain cleavage enzyme activity on human placental mito-
chondrias. This is the first report on the aromatase inhibitory 
activity of this group of natural compounds. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The biosynthesis of estrogens is catalysed by the enzyme 
complex aromatase. The complex is formed by a member of 
the superfamily of enzymes known collectively as cytochrome 
P450, namely, aromatase cytochrome P450 (P450arom, the 
product of CYP19 gene). Associated with the P450arom is a 
flavoprotein, the N A D P H cytochrome P450 reductase. These 
two enzymes catalyse the aromatization of the A ring of an-
drogens to form the phenolic ring characteristic of estrogens. 
This reaction involves three sequential oxidations to the C-19 
methyl group of the substrate, followed by elimination of C-
19 as formic acid and aromatization of the A ring. This re-
action is the only one in vertebrates that introduces an aro-
matic ring into a molecule [1]. Regulation of this enzyme plays 
an important role in many physiological processes and in 
certain diseases, the most important of which is estrogen de-
pendent breast cancer. The use of aromatase inhibitors for 
treatment of breast cancer is well demonstrated nowadays. 
The several different kinds of inhibitors investigated include 
steroidal and non-steroidal compounds which act in a com-
petitive or in a mechanism-based manner [2]. 
The plant kingdom is a very important source of medicinal 
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agents. However, few metabolites with significant aromatase 
inhibitory activity have been previously described [3]. The 
sesquiterpene lactones are a structurally diverse and extremely 
large group of metabolites with over 3500 structures thus far 
reported. Over 90% of them have been found in the Astera-
ceae, and also occur in the Acanthaceae, Anacardiaceae, 
Apiaceae, Euphorbiaceae, Lauraceae, Magnoliaceae, Menis-
permaceae, Rutaceae, Winteraceae and the Hepatidae. Bio-
medical research has established that sesquiterpene lactones 
have potential utility in the treatment of solid tumors, stom-
ach ulcers, antimigraines, cardiotonics [4] and more recently 
as inhibitors of the expression of cyclooxygenase [5] and the 
transcription factor N F - K B [6]. N o action on aromatase has 
been so far described for the sesquiterpene lactones. In this 
work we report and characterise the inhibitory effect of this 
group of compounds on human placental aromatase activity. 
2. Materials and methods 
2.1. Materials 
The sesquiterpene lactones employed in the present study have been 
isolated and characterised as previously reported. Hence, they were 
10-epi-8-deoxycumambrin B, ludartin [7], dehydroleucodin [8], peru-
vin, psilostachyin C, helenalin, psilostachyin, Sy II [9], achalensolide 
[10], Sy I [11] and eupahakonenin B [12], 
[l,2,6,7-3H]Testosterone (80 Ci/mmol) and [4-14C]Cholesterol (51 
Ci/mmol) were purchased from New England Nuclear (Boston, 
MA). Their purities were checked by thin layer chromatography. 
All other non-radioactive steroids, NADPH, DL-dithiothreitol, ethyl-
enediaminotetraacetic acid and other reagents were purchased from 
Sigma Chemical Co. (St. Louis, MO). 
2.2. Biological preparations 
Human placental microsomes (particles sedimenting at 105 000 X g 
for 60 min) were obtained as reported [13] and human placental mi-
tochondrias were obtained using the procedure described by Tuckey 
[14]. The protein concentration was determined according to the Brad-
ford procedure using BSA as standard [15]. 
2.3. Assay of aromatase activity 
The enzyme activity was determined by measuring the conversion of 
[3H]testosterone to [3H]estradiol plus [3H]estrone as described earlier 
[13]. To test the effect of different compounds on the aromatase ac-
tivity present in the microsomal fractions, varying amounts of them 
were added to the microsomes from ethanolic stock solutions. Ethanol 
alone, which did not exceed a concentration of 1% was added to 
control incubations. Values of Km and Kmax were estimated graphi-
cally from plots of l/V vs. US using linear regression analysis. The 
replots from the slope of each reciprocal plot versus the corresponding 
inhibitor concentrations were generated and the K\ values for these 
compounds were determined. 
2.4. Assay of cholesterol side-chain cleavage enzyme activity 
The enzyme activity was determined by measuring the conversion of 
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Fig. 1. Structures of sesquiterpene lactones and their IC50 values for aromatase activity in human placental microsomes. Values represent the 
average of duplicate determinations in two separate experiments. Substrate = 50 nM testosterone. 
[14C]cholesterol to [14C]pregnenolone plus [14C]progesterone as de-
scribed by Robinson et al. [16] with some modifications. The com-
pounds were added to the mitochondrias from ethanolic stock solu-
tions. Ethanol alone, which did not exceed a concentration of 1%, was 
added to the control incubations. After a preincubation time of 5 min 
the reaction was started by adding 0.1 ml of a mixture of 
[14C]cholesterol (80000 cpm/ml) sonicated in the presence of Tween 
80 [17]. The final concentration of substrate was 1.5 uM and the final 
concentration of detergent was 20 ug/ml. The reaction was linear for 
at least 4 h. Cholesterol side-chain cleavage enzyme activity was ex-
pressed as a percentage of radioactivity found in [14C]pregnenolone 
plus [14C]progesterone divided by the total radioactivity. The choles-
terol side-chain cleavage enzyme inhibitory activity of the compounds 
was assessed in terms of 50% inhibitory concentration. 
2.5. Spectral studies 
Spectroscopic studies were carried out as described by Kellis and 
Vickery [18]. Spectra were recorded with an UV 1601 PC/UV Shimad-
zu spectrophotometer interfaced to an UV/PC personal spectroscopy 
software. The protein concentration was 6.0-10.0 mg/ml. Briefly, ar-
omatase cytochrome P450 was extracted from human placental micro-
somes with 0.5% sodium cholate in the presence of 1 uM of testoster-
one. The detergent-solubilized enzyme was collected as a 55% 
saturated ammonium sulphate pellet and dialysed against 0.05 M 
sodium phosphate buffer (pH 7.2). A baseline spectrum was recorded 
with enzyme and substrate (0.25 uM testosterone) in the sample and 
reference cells and then, different concentrations of the compounds 
were added to the sample cell (solvent dimethyl sulfoxide alone was 
added to the reference). Repeated spectra were recorded to ensure 
sample equilibration and 3-5 spectra were routinely signal averaged. 
The reported apparents binding constants (Kslipp) were calculated us-
ing standard graphical analysis. Values represent the mean of three 
experiments. 
2.6. Molecular modelling 
The structures of the inhibitors and substrates were minimised using 
AMI calculations with MOPAC. 
3. Results 
Eleven sesquiterpene lactones of different skeleton-type, 
shown in Fig. 1, were tested for aromatase inhibitory activity. 
None of the compounds were found to stimulate enzyme ac-
tivity. Compounds 1 7 produced dose-dependent inhibition of 
aromatase with IC50 values ranging from 7 to 110 (0,M, while 
compounds 8-11 were inactive (Fig. 1). 
The most active compounds, 1-3 (10-epi-8-deoxycumam-
brin B, dehydroleucodin and ludartin, respectively), belong 
to the same skeleton-type (guaianolide with trans-fusion of 
the y-lactone ring to C-6). For this reason we performed a 
more detailed study of their inhibition mechanisms. Fig. 2A 
shows the time course of the aromatization of 50 pmol of 
testosterone in 1.0 ml (100000 cpm/ml) by human placental 
microsomes in the presence and absence of compound 1. 
Under these conditions, 10 u,M of the compound inhibited 
the aromatization by approximately 70% (Fig. 2A, inset). 
The reaction rate in the presence of the inhibitor remains 
linear for 10 min. The lack of time-dependence of inhibition 
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Fig. 2. (A) Time course of aromatization in microsomes in presence and absence of compound 1(10 uM). Samples contained 100 ug of protein 
and 50 pmol of testosterone in 1.0 ml. The inset shows the activity of the inhibited sample as percentage of that of the control at each time. 
(B) Kinetic analysis of inhibition of testosterone aromatization in human placental microsomes by compound 1. Inset, slopes of lines in double 
reciprocal plot vs. inhibitor concentration. Each point represents the mean of three experiments performed in duplicate. 
indicates that no significant conversion of the inhibitor to 
more or less active forms, occurs during the incubation; sim-
ilar results were obtained with compounds 2 and 3. In addi-
tion, when human placental microsomes were pre-incubated 
in presence of 10 uM of compounds 1-3 and absence of sub-
strate, variation of the pre-equilibration time failed to affect 
the fractional inhibition or time course (data not shown). 
Kinetic analyses were also performed to investigate the mech-
anism by which the sesquiterpene lactones inhibit aromatase 
enzyme activity. Fig. 2B shows a Lineweaver-Burk plot of the 
inhibition of human placental aromatase by compound 1. In-
hibition was competitive with respect to the substrate testos-
terone and a replot of the slopes of the lines (shown in the 
inset) yielded a K[ value of 4 uM for compound 1. Similar 
results were obtained for compounds 2 (Äj = 21 uJVI) and 3 
(Ki = 23 uM) (data not shown). In the absence of inhibitors, 
the Km of testosterone averaged 38 nM. 
The kinetic analyses suggested that compounds 1-3 may 
inhibit aromatization by competing with testosterone for the 
substrate binding site of the enzyme. This possibility was fur-
ther investigated by monitoring the effects of these com-
pounds on the absorption spectral properties of the enzyme. 
The difference spectra for compounds 1-3 together with that 
obtained for aminoglutethimide, a classical type II binder, are 
displayed in Fig. 3. When partially purified aromatase was 
first equilibrated with testosterone, addition of compound 1 
produced a type II difference spectrum with a Soret peak at 
419 run. This type of spectrum reflected substrate displace-
ment and conversion of the high spin aromatase cytochrome 
P450 to a low spin complex. Graphical analysis of the titra-
tion showed only one kind of binding site which exhibits a 
^sapp of 29 u.M. A similar difference spectrum was obtained 
for compound 2, showing a spectral binding constant CKsapp) 
of 40 uM. Compound 3 showed a plain curve difference spec-
trum. When compound 1 was added to aromatase in absence 
of the substrate (testosterone), no spectral changes were ob-
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Fig. 3. Difference spectra obtained upon interaction of compound 1 
[100 uM] (line 1), compound 2 [100 uM] (line 2), compound 3 [100 
uM] (line 3) and aminoglutethimide [100 uM] (dotted line) with par-
tially purified aromatase from human placenta. The samples con-
tained 0.25 uM of testosterone and the protein concentration was 
7.5 mg/ml. 
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served. This result is similar to that observed for 7,8-benzo-
flavone, another natural non-steroidal inhibitor [18]. 
Some non-steroidal aromatase inhibitors exhibit dose-de-
pendent effects on other cytochromes P450 mediated steroid 
hydroxylations. The cholesterol side-chain cleavage enzyme 
catalyses the three hydroxylations required for the conversion 
of cholesterol to pregnenolone. This enzyme is highly affected 
by aminoglutethimide [19]. We compared the capacity of ami-
noglutethimide and compounds 1 to 3 for inhibiting the ac-
tivity of this enzyme present in human placental mitochon-
drias. Aminoglutethimide inhibited this enzyme activity at 100 
uM by 50% but no significant inhibitory activity was obtained 
for compounds 1-3 in the range of concentrations tested ( 1 -
200 |J.M). Fig. 4 shows a dose-response curve for the activity 
of aminoglutethimide and compound 1. 
4. Discussion 
Several natural products inhibit the aromatase enzyme, but 
the most relevant inhibitors belong to the groups of flavo-
noids [18,20], lignans [21] and tobacco alkaloids [22]. In this 
report we show that sesquiterpene lactones exhibit competitive 
inhibition of human placental aromatase activity in a range of 
concentrations similar to the other plant-derived inhibitors 
reported previously. 
On the basis of the kinetic evidences, spectral data, molec-
ular modelling of our compounds and previous work on 
three-dimensional model of aromatase [23], we propose a 
mechanism of action of compounds 1-3. These compounds 
are structurally related and differ on the substitution pattern 
and oxidation state of carbons C-l, C-2, C-3, C-4, C-10, C-14 
and C-l5. At first glance, we observed a relationship between 
the activity and the position of the oxygen atom at C-10 (OH 
in compound 1), at C-2 (carbonyl in compound 2) and at C-3, 
.1 1.0 10.0 100.0 
Inhibitor (|iM) 
Fig. 4. Comparative effects of compound 1 and aminoglutethimide 
on cholesterol side-chain cleavage enzyme activity (CSCC) present 
in human placental mitochondrias. The cholesterol concentration 
was 1.5 u.M. Each point represents the mean of two experiments 
performed in duplicate. 
Compound 1 (10-epi-8-deoxycumarabrin B) 
Compound 2 (Dehydroleucodin) Compound 3 (Ludartin) 
Fig. 5. Three-dimensional models of compound 1 (10 epi-8-deoxycu-
mambrin B), compound 2 (dehydroleucodin) and compound 3 (lu-
dartin). 
C-4 (epoxide in compound 3). From the three-dimensional 
computer generated model of 1-3 shown in Fig. 5, it is pos-
sible to see that: (a) in compound 1 the OH group is above 
the plane of the C-10 member ring, (b) in compound 2 the 
oxygen appears as a carbonyl group attached to C-2 and 
aligned in the plane of the molecule and, (c) in compound 3 
the oxygénation is below the plane of the molecule as an 
epoxide group at C-3, C-4. These displacements of the oxy-
génation in the guaianolide nucleus from top to bottom in the 
plane of the molecule is accompanied by a decreasing inhib-
itory activity. 
The type II difference spectra obtained for compounds 1 
and 2 and not for compound 3, indicate that compounds 1 
and 2 have the ability to coordinate to the heme iron at the 
active site. Besides, according to their spectra, compound 1 
coordinates better than compound 2. 
During the aromatization reaction, the substrate (androste-
nedione or testosterone) has been suggested to position in the 
active site in such a manner that the methyl group C-l9 is 
directed toward the heme iron, which directly participates in 
the three sequential oxidation of this methyl group. Besides, 
according to the aromatase model proposed by Graham-Lor-
ence et al. [23], the substrate is fixed in the active site via 
interaction of the C-3 carbonyl group with K473 (lysine) 
and the 17-keto group of the androstenedione or the 17-OH 
of the testosterone to the H128 (histidine), stabilising the sub-
strate and holding the C-l9 methyl near the heme iron. In our 
case, we superimposed the models of compound 1 and testos-
terone by overlapping by hand the carbonyl group of com-
pound 1 and the carbonyl group at C-3 of testosterone. We 
thus found a combination of both structures in which the 
hydroxyl group at C-10 of compound 1 is spatially close to 
the C-l9 methyl group of testosterone (Fig. 6). This proximity 
in space would indicate that in analogy with the model pro-
posed by Graham-Lorence et al. [23], the carbonyl group of 
the lactone would interact with the K473 residue and the OH 
group at C-10 would coordinate to the heme iron during the 
inhibition mechanism. In the case of compound 2, which 
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Fig. 6. Three-dimensional models of compound 1 (dotted line) and 
testosterone (full line). The models are superimposed by overlapping 
by hand the carbonyl group at C-12 of compound 1 and the car-
bonyl group at C-3 of testosterone. S, steroid; L, sesquiterpene lac-
tone. 
shows a weaker type II difference spectra, the carbonyl oxygen 
at C-2 seems to be responsible of coordinating to the heme 
iron. Considering that the coordination capacity of a ketone 
carbonyl is similar to an alcohol [24], the weaker type II 
spectra and the weaker activity shown by compound 2 may 
be due to the fact that carbonyl group at C-2 is farther from 
the heme iron than the OH of compound 1. In the case of 
compound 3 the epoxide group is in the a face of the molecule 
and close to the lactone carbonyl group, which may explain 
why this compound is less active than 1 and 2, and does not 
present a type II spectra. On the other hand, the small size of 
these inhibitors compared with the steroidal nucleus seems to 
be a limitation for the possible interactions with the relatively 
large active site of the enzyme. 
5. Conclusions 
As a result of our investigation we can conclude that we are 
in presence of a new group of natural non-steroidal inhibitors 
of the aromatase enzyme complex. Besides, the three most 
potent inhibitors here described (1, 2 and 3) have shown to 
be: (a) competitive with respect to the substrate testosterone; 
(b) more specific than aminoglutethimide, since they do not 
aifect the activity of the cholesterol side chain cleavage en-
zyme, the first step of the steroidogenesis; (c) compounds 1 
and 2 act as type II ligands to the heme iron present in the 
active site of aromatase cytochrome P450. 
To our knowledge there are few guaianolides with a C-10 
hydroxyl group ß-orientated and all were isolated from the 
genus Stevia from north-western of Argentina [7,25]. This 
uncommon stereochemistry opens interesting perspectives for 
the design of future modifications on the sesquiterpene nu-
cleus in order to enhance its aromatase inhibitory activity. 
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